- Home
- EBR vs NBIX Comparison
EBR vs NBIX Comparison
Compare EBR & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBR
- NBIX
- Stock Information
- Founded
- EBR 1962
- NBIX 1992
- Country
- EBR Brazil
- NBIX United States
- Employees
- EBR N/A
- NBIX N/A
- Industry
- EBR Electric Utilities: Central
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EBR Utilities
- NBIX Health Care
- Exchange
- EBR Nasdaq
- NBIX Nasdaq
- Market Cap
- EBR 12.5B
- NBIX 13.7B
- IPO Year
- EBR N/A
- NBIX 1996
- Fundamental
- Price
- EBR $5.78
- NBIX $143.26
- Analyst Decision
- EBR
- NBIX Buy
- Analyst Count
- EBR 0
- NBIX 22
- Target Price
- EBR N/A
- NBIX $164.81
- AVG Volume (30 Days)
- EBR 2.1M
- NBIX 1.0M
- Earning Date
- EBR 02-10-2025
- NBIX 02-05-2025
- Dividend Yield
- EBR 3.81%
- NBIX N/A
- EPS Growth
- EBR 249.43
- NBIX 97.40
- EPS
- EBR 0.84
- NBIX 3.73
- Revenue
- EBR $6,993,057,205.00
- NBIX $2,242,800,000.00
- Revenue This Year
- EBR $8.84
- NBIX $27.07
- Revenue Next Year
- EBR $1.88
- NBIX $17.14
- P/E Ratio
- EBR $6.94
- NBIX $38.43
- Revenue Growth
- EBR 5.06
- NBIX 25.72
- 52 Week Low
- EBR $5.45
- NBIX $110.95
- 52 Week High
- EBR $9.11
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- EBR 49.84
- NBIX 66.20
- Support Level
- EBR $5.70
- NBIX $138.66
- Resistance Level
- EBR $5.87
- NBIX $144.24
- Average True Range (ATR)
- EBR 0.16
- NBIX 3.23
- MACD
- EBR 0.03
- NBIX 0.07
- Stochastic Oscillator
- EBR 73.33
- NBIX 82.29
About EBR Centrais Electricas Brasileiras S A (Each representing one Common Share)
Centrais Eletricas Brasileiras SA is engaged in the generation, transmission, and commercialization of electricity in Brazil. The company operates a portfolio of wind, thermal, hydro, and nuclear power plants located throughout the country. Its segments are Generation which consists of the generation of electric energy and the sale of energy to distribution companies and free consumers, and commercialization; Transmission which consists of the transmission of electric energy; and Administration activities mainly represent the Company's cash management, the management of the compulsory loan, and the management of business in SPEs, and others.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.